Abstract：
We aim to retrospectively explore the guiding value of the Lauren classification for patients who have undergone D2 gastrectomy to choose oxaliplatin plus capecitabine (XELOX) or oxaliplatin plus S-1 (SOX) as a further systemic treatment after the operation.
We collected data of 406 patients with stage III gastric cancer(GC)after radical D2 resection and regularly received XELOX or SOX adjuvant treatment after surgery and followed them for at least five years. According to the Lauren classification, we separated patients out into intestinal type (IT) GC together with non-intestinal type(NIT) GC. According to the chemotherapy regimen, we separated patients into the SOX group together with the XELOX group.
Among non-intestinal type patients, the 3-year DFS rates in the SOX group and the XELOX group were 72.5%, respectively; 54.5% (P=0.037); The 5-year OS rates were 66.8% and 51.8% respectively (P=0.038), both of which were statistically significant.
The patients of non-intestinal type GC may benefit from the SOX regimen. Differences were counted without being statistically significant with intestinal-type GC in the SOX or XELOX groups.
We collected data of 406 patients with stage III gastric cancer(GC)after radical D2 resection and regularly received XELOX or SOX adjuvant treatment after surgery and followed them for at least five years. According to the Lauren classification, we separated patients out into intestinal type (IT) GC together with non-intestinal type(NIT) GC. According to the chemotherapy regimen, we separated patients into the SOX group together with the XELOX group.
Among non-intestinal type patients, the 3-year DFS rates in the SOX group and the XELOX group were 72.5%, respectively; 54.5% (P=0.037); The 5-year OS rates were 66.8% and 51.8% respectively (P=0.038), both of which were statistically significant.
The patients of non-intestinal type GC may benefit from the SOX regimen. Differences were counted without being statistically significant with intestinal-type GC in the SOX or XELOX groups.
摘要：
背景：我们旨在回顾性探讨Lauren分类对D2胃切除术后选择奥沙利铂联合卡培他滨（XELOX）或奥沙利铂联合S-1（SOX）作为术后进一步全身治疗的患者的指导价值。
方法：我们收集了406例III期胃癌（GC）患者D2根治术后的数据，术后定期接受XELOX或SOX辅助治疗，并随访至少5年。根据劳伦的分类,我们将患者分为肠型（IT）GC和非肠型（NIT）GC。根据化疗方案,我们将患者分为SOX组和XELOX组.
结果：在非肠道型患者中，SOX组和XELOX组的3年DFS率为72.5%,54.5%(P=0.037);5年OS率分别为66.8%和51.8%(P=0.038),两者均具有统计学意义。
结论：非肠道型GC患者可能受益于SOX方案。在SOX或XELOX组中，肠道型GC的差异无统计学意义。
方法：我们收集了406例III期胃癌（GC）患者D2根治术后的数据，术后定期接受XELOX或SOX辅助治疗，并随访至少5年。根据劳伦的分类,我们将患者分为肠型（IT）GC和非肠型（NIT）GC。根据化疗方案,我们将患者分为SOX组和XELOX组.
结果：在非肠道型患者中，SOX组和XELOX组的3年DFS率为72.5%,54.5%(P=0.037);5年OS率分别为66.8%和51.8%(P=0.038),两者均具有统计学意义。
结论：非肠道型GC患者可能受益于SOX方案。在SOX或XELOX组中，肠道型GC的差异无统计学意义。
